SecBot SecBot
SECBOTREPLAY Home › Report › SLS

SLS · $150M priced offering at $13.00

SELLAS Life Sciences Group, Inc. · 424B5 filed Nov 19, 2026 at 16:07 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Nov 19, 2026 at 16:07 ET

SELLAS Life Sciences Group priced a $150M underwritten public offering of 11,538,462 shares at $13.00 per share, a 27.6% discount to the prior day's $17.95 close. The offering follows positive Phase 3 REGAL trial results announced November 17, 2026 and Q3 2026 earnings reported November 12, 2026. Net proceeds of approximately $140.6M will fund clinical development and commercialization activities.

  • 11,538,462 shares offered at $13.00 per share, a 27.6% discount to the $17.95 closing price on November 18, 2026
  • Total offering size of $150,000,006; net proceeds of approximately $140.6M ($161.8M if underwriters exercise full option)
  • Underwriters have a 30-day option to purchase up to an additional 1,730,769 shares
  • Shares outstanding will increase from 203,527,833 to 215,066,295 (5.7% dilution), or 216,797,064 if option exercised (6.5% dilution)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access